» Articles » PMID: 32929754

Systemic Amyloidosis from A (AA) to T (ATTR): a Review

Overview
Journal J Intern Med
Specialty General Medicine
Date 2020 Sep 15
PMID 32929754
Citations 90
Authors
Affiliations
Soon will be listed here.
Abstract

Systemic amyloidosis is a rare protein misfolding and deposition disorder leading to progressive organ failure. There are over 15 types of systemic amyloidosis, each caused by a different precursor protein which promotes amyloid formation and tissue deposition. Amyloidosis can be acquired or hereditary and can affect various organs, including the heart, kidneys, liver, nerves, gastrointestinal tract, lungs, muscles, skin and soft tissues. Symptoms are usually insidious and nonspecific resulting in diagnostic delay. The field of amyloidosis has seen significant improvements over the past decade in diagnostic accuracy, prognosis prediction and management. The advent of mass spectrometry-based shotgun proteomics has revolutionized amyloid typing and has led to the discovery of new amyloid types. Accurate typing of the precursor protein is of paramount importance as the type dictates a specific management approach. In this article, we review each type of systemic amyloidosis to provide the practitioner with practical tools to improve diagnosis and management of these rare disorders.

Citing Articles

Acute Myocarditis and Inflammatory Cardiomyopathies: Insights From Cardiac Magnetic Resonance Findings.

Lauriero F, Vita C, Perazzolo A, Sanseverino G, Moliterno E, Rovere G Echocardiography. 2025; 42(2):e70099.

PMID: 39963997 PMC: 11834149. DOI: 10.1111/echo.70099.


Advances in genetic diagnosis and therapy of hereditary heart disease: a bibliometric review from 2004 to 2024.

Ma H, Wang Y, Jia Y, Xie L, Liu L, Zhang D Front Med (Lausanne). 2025; 11():1507313.

PMID: 39845823 PMC: 11750821. DOI: 10.3389/fmed.2024.1507313.


Amyloidosis in Childhood: A Review of Clinical Features and Comparison with Adult Forms.

Zamarra G, Sandu M, Caione N, Di Pasquale G, Di Berardino A, Di Ludovico A J Clin Med. 2024; 13(22).

PMID: 39597824 PMC: 11594867. DOI: 10.3390/jcm13226682.


A review of recent clinical trials to evaluate disease-modifying therapies in the treatment of cardiac amyloidosis.

Senigarapu S, Driscoll J Front Med (Lausanne). 2024; 11:1477988.

PMID: 39540049 PMC: 11557331. DOI: 10.3389/fmed.2024.1477988.


Assessing left atrial dysfunction in cardiac amyloidosis using LA-LV strain slope.

Edbom F, Lindqvist P, Wiklund U, Pilebro B, Anan I, Flachskampf F Eur Heart J Imaging Methods Pract. 2024; 2(3):qyae100.

PMID: 39530018 PMC: 11551613. DOI: 10.1093/ehjimp/qyae100.